Fig. 6

The cyclooxygenase (COX1/2) inhibitor indomethacin enhanced the anti-tumour effects of AVE8134. a1–a3 Representative bands of COX1, COX2, and β-actin and the cartogram of COX1/β-actin and COX2/β-actin in HUVECs at the indicated treatment evaluated by western blot (n ≥ 3). ns = not significant. b The ratio of COX2 activity to total COX activity in TC-1 tumour lysates (n = 6). ^*P < 0.05 vs control; ^#P < 0.05 vs AVE. c1 and c2 Images of TC-1 primary xenograft tumours and their growth curves in mice treated with AVE, indomethacin, or both together (n = 8). ^*P < 0.05 vs control; ^##P < 0.01 vs AVE or indomethacin. d and e Levels of EETs and 11-HETE in HUVECs treated with AVE, indomethacin, or both together (n = 6). ^*P < 0.05 vs control; ^#P < 0.05 vs AVE. f1–f3 Representative bands of CD31, Cyp2c44, and β-actin and the cartogram of CD31/β-actin and Cyp2c44/β-actin from TC-1 tumours at the indicated treatment, as evaluated by western blot. ^*P < 0.05 vs control; ^#P < 0.05 vs AVE (n ≥ 3)